7,755 Shares in Solventum Co. (NYSE:SOLV) Bought by Oak Thistle LLC

Oak Thistle LLC acquired a new stake in Solventum Co. (NYSE:SOLV) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 7,755 shares of the company’s stock, valued at approximately $512,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Hollencrest Capital Management acquired a new position in shares of Solventum during the second quarter worth $25,000. Modus Advisors LLC purchased a new stake in Solventum during the 4th quarter worth $25,000. Copeland Capital Management LLC purchased a new stake in Solventum during the 3rd quarter worth $26,000. Mather Group LLC. acquired a new position in Solventum in the 3rd quarter worth $27,000. Finally, Twin Lakes Capital Management LLC acquired a new stake in shares of Solventum during the second quarter valued at about $29,000.

Solventum Price Performance

Solventum stock opened at $72.72 on Friday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The firm’s 50-day moving average is $69.14 and its 200-day moving average is $65.29. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15.

Wall Street Analysts Forecast Growth

SOLV has been the topic of several recent analyst reports. Wolfe Research assumed coverage on Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating on the stock. Morgan Stanley increased their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. Stifel Nicolaus initiated coverage on shares of Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. Piper Sandler raised their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Finally, Mizuho started coverage on shares of Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price on the stock. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $68.29.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.